Theradaptive Granted Breakthrough Device Designation

Theradaptive was granted a second Breakthrough Medical Device designation from FDA for its OsteoAdapt SP Spinal Fusion implant. The device is indicated for posterolateral spinal fusion to treat degenerative disc disease, spondylolisthesis or retrolisthesis.

The company's first breakthrough designation was granted in late 2021.

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us